
Markus Dold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1875525/publications.pdf Version: 2024-02-01



MADRILS DOLD

#	Article	IF	CITATIONS
1	Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia. JAMA Psychiatry, 2016, 73, 199.	11.0	235
2	Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 2013, 16, 557-574.	2.1	141
3	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatrica Scandinavica, 2019, 139, 78-88.	4.5	92
4	Evidence-based pharmacotherapy of treatment-resistant unipolar depression. International Journal of Psychiatry in Clinical Practice, 2017, 21, 13-23.	2.4	90
5	Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice. World Journal of Biological Psychiatry, 2019, 20, 427-448.	2.6	89
6	Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. International Journal of Neuropsychopharmacology, 2015, 18, pyv047.	2.1	83
7	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. Journal of Psychiatric Research, 2017, 91, 1-13.	3.1	77
8	Refining Prediction in Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2018, 79, 16m11385.	2.2	76
9	Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials. Psychotherapy and Psychosomatics, 2015, 84, 110-116.	8.8	74
10	The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials. Psychotherapy and Psychosomatics, 2020, 89, 17-24.	8.8	65
11	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). International Journal of Neuropsychopharmacology, 2018, 21, 539-549.	2.1	54
12	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study. European Neuropsychopharmacology, 2016, 26, 1960-1971.	0.7	50
13	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). European Neuropsychopharmacology, 2018, 28, 752-760.	0.7	47
14	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. British Journal of Psychiatry, 2019, 214, 36-41.	2.8	44
15	International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. Pharmacological Reviews, 2018, 70, 475-504.	16.0	42
16	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. Acta Psychiatrica Scandinavica, 2018, 137, 401-412.	4.5	37
17	Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials. Psychotherapy and Psychosomatics, 2017, 86, 283-291.	8.8	32
18	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. Journal of Affective Disorders, 2018, 227, 777-786.	4.1	32

MARKUS DOLD

#	Article	IF	CITATIONS
19	Combining machine learning algorithms for prediction of antidepressant treatment response. Acta Psychiatrica Scandinavica, 2021, 143, 36-49.	4.5	31
20	Psychotic Features in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	2.2	28
21	Dose escalation of antipsychotic drugs in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Research, 2015, 166, 187-193.	2.0	24
22	Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment. International Journal of Neuropsychopharmacology, 2020, 23, 440-445.	2.1	23
23	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109638.	4.8	20
24	Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 293-302.	3.2	20
25	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study. European Neuropsychopharmacology, 2017, 27, 625-632.	0.7	19
26	Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study. European Neuropsychopharmacology, 2019, 29, 777-785.	0.7	18
27	Sexâ€related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. Depression and Anxiety, 2021, 38, 896-906.	4.1	18
28	Melancholic features in major depression – a European multicenter study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110285.	4.8	17
29	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study. European Neuropsychopharmacology, 2018, 28, 1305-1313.	0.7	15
30	Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry, 2015, 14, 304-306.	10.4	14
31	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. European Neuropsychopharmacology, 2020, 41, 70-80.	0.7	14
32	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. Journal of Psychiatric Research, 2021, 141, 167-175.	3.1	14
33	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 715-727.	3.2	14
34	Increasing placebo response in antipsychotic trials: a clinical perspective. Evidence-Based Mental Health, 2015, 18, 77-79.	4.5	10
35	Rapid antidepressant effect of S-ketamine in schizophrenia. European Neuropsychopharmacology, 2018, 28, 980-982.	0.7	7
36	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder – Findings from a European multicenter study. Journal of Affective Disorders, 2018, 227, 254-259.	4.1	6

MARKUS DOLD

#	Article	IF	CITATIONS
37	Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression. Journal of ECT, 2017, 33, e31-e32.	0.6	5
38	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. International Journal of Neuropsychopharmacology, 2020, 23, 571-577.	2.1	5
39	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. World Journal of Biological Psychiatry, 2016, 17, 210-220.	2.6	4
40	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. Journal of Affective Disorders, 2021, 286, 149-157.	4.1	4
41	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 51-63.	3.2	4
42	How to prevent and manage hyperammonemic encephalopathies in valproate therapy. Journal of Affective Disorders Reports, 2021, 5, 100186.	1.7	3
43	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. Journal of Affective Disorders, 2022, 296, 485-492.	4.1	3
44	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 114, 110480.	4.8	3
45	Intramuscular maintenance treatment with ultra-high-dose long-acting injectable aripiprazole in an elderly patient suffering from chronic refractory schizophrenia: A case report. European Psychiatry, 2016, 33, S573-S573.	0.2	2
46	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2021, , .	2.1	2
47	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. Journal of Affective Disorders, 2022, 312, 225-234.	4.1	2
48	Does a high degree of instability during psychotherapy enhance a positive therapy-response? - an evaluation of an in-patient behavior therapy of obsessive-compulsive disorder. European Psychiatry, 2011, 26, 1303-1303.	0.2	0
49	Antipsychotics in obsessive-compulsive disorder - an auspicious approach for treatment-resistant patients?. European Psychiatry, 2011, 26, 1236-1236.	0.2	Ο
50	P02 - 369 - Neuroimaging of the various symptom dimensions in obsessive - compulsive disorder - a systematic review. European Psychiatry, 2011, 26, 965-965.	0.2	0
51	Systematic evaluation of dose-escalation strategies after initial non-response to standard-dose pharmacotherapy in schizophrenia. European Psychiatry, 2017, 41, S193-S193.	0.2	Ο
52	Alternating intravenous racemic ketamine and electroconvulsive therapy in treatment resistant depression: A case report. European Psychiatry, 2017, 41, S522-S522.	0.2	0
53	Prescribing patterns of psychiatric drugs in major depressive disorder–ÂFindings from a large European multicenter, cross-sectional study. European Psychiatry, 2017, 41, S367-S367.	0.2	Ο
54	Doseâ€response relationship of selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica, 2020, 142, 427-429.	4.5	0